Trelegy Ellipta 200 ug/1

Trelegy Ellipta 200 ug/1 is a combination inhaler containing fluticasone furoate, umeclidinium bromide, and vilanterol trifenatate. It is designed for respiratory conditions, offering a convenient once-daily treatment option. This powder inhaler is manufactured by GlaxoSmithKline LLC in the USA.

Trelegy Ellipta 200 ug/1 is primarily used for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It combines three active ingredients to help manage symptoms such as wheezing, shortness of breath, and coughing. This inhaler is designed for long-term use and is not intended for immediate relief of sudden breathing problems.

Common effects of Trelegy Ellipta 200 ug/1 may include throat irritation, headache, and a dry mouth. Some users might experience hoarseness or a fungal infection in the mouth. These effects are generally mild and temporary, but persistent or severe symptoms should be discussed with a healthcare provider.

Trelegy Ellipta 200 ug/1 should be used as directed by a healthcare provider. It is important to follow the proper inhalation technique to ensure effective delivery of the medication. Regular monitoring may be required, especially for individuals with a history of asthma or other respiratory conditions. Always store the inhaler in a clean, dry place.

Trelegy Ellipta 200 ug/1 may interact with other medications, including beta-blockers, diuretics, and certain antifungal or antibiotic treatments. It is important to inform your healthcare provider about all medications you are taking to avoid potential interactions. Alcohol and other respiratory depressants should be used with caution.